BPMUF Stock UPDATES Basilea Pharmaceutic (BPMUF) 112.4278 08/28/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Basilea Pharmaceutic (BPMUF) 112.4278 $BPMUF

European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review
GlobeNewswire - Thu Aug 21, 12:20AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that the European Medicines Agency (EMA) has accepted its isavuconazole Marketing Authorization Application (MAA) for review. Basilea's MAA seeks approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis (zygomycosis) in adults.

Basilea appoints Chief Commercial Officer
GlobeNewswire - Mon Aug 18, 12:21AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that it has appointed David Veitch as Chief Commercial Officer of Basilea Pharmaceutica International Ltd. Mr Veitch will join the company on September 1, 2014. As a member of the management committee, he will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access, reporting to Chief Executive Officer Ronald Scott.

Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014
Thomson Reuters ONE - Thu Aug 14, 12:16AM CDT
Basilea Pharmaceutica AG / Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Dotmatics Announce Speaker Line-up for User Group Meeting 2014
PR Newswire Europe - Wed Jul 23, 8:59AM CDT
BISHOPS STORTFORD, England, July 23, 2014 /PRNewswire/ --

Basilea to introduce the antibiotic ceftobiprole medocaril in Europe through Quintiles
M2 - Mon Jul 21, 7:59AM CDT
Pharmaceutical products company Basilea Pharmaceutica (Munich K5.MU) Monday announced an agreement for the commercialisation of Zevtera/Mabelio (ceftobiprole medocaril) in Europe through Quintiles (NYSE:Q).

Basilea to launch Zevtera(r)/Mabelio(r) (ceftobiprole medocaril) in Europe through a commercial services provider
GlobeNewswire - Mon Jul 21, 12:23AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that it has entered into an agreement with Quintiles (NYSE: Q) for the commercialization of Zevtera(R)/Mabelio(R) (ceftobiprole medocaril) in Europe.

Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections
Thomson Reuters ONE - Thu Jul 17, 1:46AM CDT
Basilea Pharmaceutica AG / Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis
Thomson Reuters ONE - Thu Jul 17, 1:45AM CDT
Basilea Pharmaceutica AG / Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the European Commission granted isavuconazole orphan drug designations for the treatment of invasive aspergillosis and mucormycosis (zygomycosis). Isavuconazole is an investigational intravenous and oral broad-spectrum antifungal.

Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis
Thomson Reuters ONE - Wed Jul 09, 10:32PM CDT
Basilea Pharmaceutica AG / Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Basilea announces start of phase 2a study with oncology drug candidate BAL101553
Thomson Reuters ONE - Thu Jun 26, 9:46PM CDT
Basilea Pharmaceutica AG / Basilea announces start of phase 2a study with oncology drug candidate BAL101553 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Basilea provides update on ceftobiprole's U.S. regulatory status
Thomson Reuters ONE - Thu Jun 26, 9:45PM CDT
Basilea Pharmaceutica AG / Basilea provides update on ceftobiprole's U.S. regulatory status . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 10

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 71

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading

Top 5 Most Recently Viewed Articles

ParagonX Holdings: Update on Company Transformation Plans

Updated Category News Views 146

ParagonX Holdings Shareholder Update ParagonX Holdings, Inc. (OTC:CAVR) recently shared insightful information regarding its transformation and strategic direction. The company is under the management of Caprino Management, LLC, which is actively assessing acquisition opportunities to bolster its growth. Divestitures and Debt Restructuring A significant step taken by...

Continue Reading
Applaud Receives Prestigious AI Award for Transforming HR

Updated Category News Views 300

Applaud Triumphs with Prestigious AI Award Applaud, a leading innovator in HR technology, has achieved significant recognition in the tech industry. The company’s generative-AI HR platform was awarded the flagship AI Award at a major international event. Applaud was selected among several finalists, showcasing its commitment to providing measurable value to employees...

Continue Reading
Empowering Stories: A Mother's Journey to a New Start

Updated Category News Views 257

Empowering Stories: A Mother's Journey to a New Start Anita's story is one of resilience. Faced with overwhelming challenges in her early life, she fought tirelessly to change her circumstances. Growing up without a family, she was married at a tender age to an older man, and for years, she juggled the responsibilities of motherhood while tending to her husband’s...

Continue Reading
First Capital REIT Declares Monthly Distribution for Investors

Updated Category News Views 176

First Capital REIT Announces Distribution for October 2025 First Capital REIT announces its cash distribution for October 2025, setting a notable precedent for its unitholders. The company has declared a distribution of $0.074167 per REIT unit, which translates to an annualized payout of $0.89 per unit. The payment is scheduled for November 17, 2025, to unitholders...

Continue Reading
Sidus Space and Other Major Stocks Experience Declines

Updated Category News Views 166

Stock Market Dynamics: Sidus Space and Others The U.S. stock market is seeing some fluctuations as futures showed little movement earlier today. Among these movements, Nasdaq 100 futures gently slipped by about 0.01%. In the midst of this, shares of Sidus Space, Inc. (NASDAQ: SIDU) are particularly noteworthy. Sidus Space's Price Adjustment Sidus Space recently made...

Continue Reading